Results 161 to 170 of about 1,955 (223)

Improvement in Physical Function Associated With Burosumab in a Patient With X-linked Hypophosphatemia: A Case Report. [PDF]

Cureus
Fukushima M, Hashida R, Matsuse H, Hiraoka K.   +3 more
europepmc   +1 more source

Early Dental Manifestations and Multidisciplinary Management of X-Linked Hypophosphatemic Rickets in a Pediatric Patient: A Case Report. [PDF]

Children (Basel)
Mitova N, Petkova-Ninova V, Popova Y.
europepmc   +1 more source

Editorial: Phosphate handling: from cells to human. [PDF]

Front Endocrinol (Lausanne)
Abate V, Menale C, De Filippo G.
europepmc   +1 more source

Health-related quality of life in French pediatric patients with X-linked hypophosphatemia: real-world data from the International XLH Registry. [PDF]

JBMR Plus
Linglart A, Amouroux C, Gueorguieva I, Harambat J, Salles JP, Ertl DA, Sandilands K, Rylands A, Williams A, Ishii H, Bowden A, Varni JW, Bacchetta J.   +12 more
europepmc   +1 more source

XLH Matters 2024: expert insights and practical tools for enhancing care of people living with X-linked hypophosphataemia. [PDF]

Orphanet J Rare Dis
Seefried L, Alzahrani AS, Wagner CA, Eade D, Fintini D, Haffner D, Frookh Jamal H, Bubbear JS, Guazzarotti L, Cheung MS, Abid N, Costa-Reis P, Ferreira Santos R, Beck-Nielsen SS, Linglart A.   +14 more
europepmc   +1 more source

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia [PDF]

Olivia de Jong, Zubeyir Hasan Gun, Afua Asante-Otoo, Ibrahim I Elbashir, Xiaobai Li, Babak Saboury, Vardit Kram, Luis F de Castro, Virginia Macdonald, Alison M Boyce   +9 more
openalex   +1 more source

The recommended starting dose of 0.4mg/kg burosumab is insufficient for most children with X-linked hypophosphatemia (XLH) - Results from the first treated patients in Sweden

, 2020
Sigrún Hallgrímsdóttir, Ola Nilsson
openalex   +1 more source

Burosumab in Chinese adults with X-linked hypophosphatemia: a phase 4 study. [PDF]

JBMR Plus
Liu W, Zhang Z, Wang Y, Pei Y, Xue Y, Ji Y, Sugimoto M, Kuriki M, Xia W.   +8 more
europepmc   +1 more source

Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients

Daisuke Takaichi, Andy Gewitz, Hiroki Okada, Krina Mehta, Jun Hosogi, Yoshinori Nagata, Kiersten Utsey, Matthew Riggs   +7 more
openalex   +1 more source

Craniosynostosis in Children with X-Linked Hypophosphatemia Treated with Burosumab: Insights from a Single Center Cross-sectional Cohort Screening [PDF]

Francesca Aiello, Francesca Romano, Adalgisa Festa, Giampiero I. Baroncelli, Giuseppe Cinalli, Mario Cirillo, Renata Conforti, Emanuele Miraglia del Giudice, Ferdinando Aliberti, Anna Grandone   +9 more
openalex   +1 more source